greeksoup/ stock research

PAVmed Inc.: Q2 FY2026 earnings call

What management said about Q2 FY2026, from the documents filed with the SEC on 14 August 2026: press release. Guidance figures: 2 new. The quarter’s numbers.

Key takeaways

  • GAAP net loss attributable to stockholders: The company reported a GAAP net loss attributable to common stockholders of about $5.5 million, or $(0.87) per diluted share. The first quarter figure was $(4.42). Source
  • OSU-The James onboarding increased: Veris increased patient onboarding at OSU-The James as the commercial phase of its strategic engagement accelerated. Clinical rollout continued across additional departments. Source
  • Implantable monitor nears design freeze: Development of the implantable physiological monitor advanced toward a planned early 2027 FDA 510(k) submission. Design freeze is nearing completion and preliminary verification and validation is under way. Source
  • EsoGuard revenue and test volume: Lucid recognized $1.5 million of EsoGuard revenue for the quarter and processed 2,770 EsoGuard tests. The first quarter figures were $1.3 million and 3,177 tests. Source
  • First laboratory benefit manager policy: Lucid secured its first laboratory benefit manager coverage policy for EsoGuard. The policy treats EsoGuard as medically necessary for patients meeting established screening criteria, and client health plans have adopted it. Source
  • Operating expenses about $7.1 million: Operating expenses were about $7.1 million for the quarter, including $0.9 million of stock-based compensation. The first quarter figures were $8.1 million and $0.2 million. Source
  • Cash balance at quarter end: Cash and cash equivalents were $3.8 million at June 30, 2026, against $6.5 million at March 31, 2026 and $1.5 million at December 31, 2025. Source

“PAVmed saw tangible progress across its core businesses during this past quarter and recent weeks,”

Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer

Guidance

AreaPeriodFigureAgainst last quarter
Regulatory submission timing, Veris implantable physiological monitor SourceEarly 2027early 2027 FDA 510(k) submissionNew
FDA meeting, PortIO pre-submission Source4Q26FDA meeting request planned for 4Q26New

What changed from last quarter

  • New guidance: The 510(k) submission for the implantable monitor is now given as early 2027. The prior release said only that a submission was planned. Source
  • New guidance: A PortIO FDA meeting request is now dated 4Q26. The prior release did not mention a PortIO FDA meeting. Source
  • New: Lucid reports its first laboratory benefit manager coverage policy for EsoGuard. The prior release did not report one. Source
  • New: Lucid reports a health economic cost-effectiveness model for EsoGuard screening, built to support payor engagement. The prior release did not mention it. Source
  • New: PortIO first-in-human results were published in a journal. The prior release did not mention them. Source
  • New: Octeris, named here as a subsidiary, reports completing an FDA pre-submission draft for its imaging probe. The prior release did not mention Octeris. Source

Consolidated results for the quarter

  • GAAP net loss attributable to stockholders: The company reported a GAAP net loss attributable to common stockholders of about $5.5 million, or $(0.87) per diluted share. The first quarter figure was $(4.42). Source
  • Non-GAAP adjusted net loss reported: The company also reported a non-GAAP adjusted net loss of about $1.7 million, or $(0.27) per share, which removes stock-based compensation and other non-cash items. Source
  • Revenue figures differ between sections: The reconciliation table reports revenue of $33 thousand for the quarter, against $6 thousand a year earlier. The Lucid section cites $1.5 million of EsoGuard revenue. The release does not reconcile the two. Source

Veris Health progress

  • OSU-The James onboarding increased: Veris increased patient onboarding at OSU-The James as the commercial phase of its strategic engagement accelerated. Clinical rollout continued across additional departments. Source
  • Implantable monitor nears design freeze: Development of the implantable physiological monitor advanced toward a planned early 2027 FDA 510(k) submission. Design freeze is nearing completion and preliminary verification and validation is under way. Source

“Veris accelerated its commercial engagement with OSU-The James while progressing development of its implantable physiological monitor toward FDA submission.”

Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer

Lucid Diagnostics commercial activity

  • EsoGuard revenue and test volume: Lucid recognized $1.5 million of EsoGuard revenue for the quarter and processed 2,770 EsoGuard tests. The first quarter figures were $1.3 million and 3,177 tests. Source
  • First laboratory benefit manager policy: Lucid secured its first laboratory benefit manager coverage policy for EsoGuard. The policy treats EsoGuard as medically necessary for patients meeting established screening criteria, and client health plans have adopted it. Source
  • Cost-effectiveness model developed: Lucid developed a health economic model of EsoGuard screening to support payor engagement. Preliminary results show improved clinical outcomes and cost-effectiveness in nearly all modeled scenarios. Source

Device portfolio milestones

  • PortIO first-in-human results published: PortIO first-in-human results appeared in the Journal of Vascular Access. They report 100% device patency, 90% completion of the intended implant duration, and no device-related adverse events. Source
  • PortIO FDA meeting planned 4Q26: PortIO's FDA pre-submission process advanced. A meeting request is planned for the fourth quarter of 2026. Source
  • Octeris probe development advanced: Octeris improved the form factor and image-processing speed of its multimodal endoscopic imaging probe. It also completed an FDA pre-submission draft. Source

“Lucid secured an important new commercial coverage policy for EsoGuard while continuing to advance its broader commercial initiatives.”

Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer

Operating costs and non-cash items

  • Operating expenses about $7.1 million: Operating expenses were about $7.1 million for the quarter, including $0.9 million of stock-based compensation. The first quarter figures were $8.1 million and $0.2 million. Source
  • Equity method fair value change added back: The non-GAAP reconciliation adds back a $2.5 million change in fair value of equity method investments for the quarter, against $10.6 million in the second quarter of 2025. Source

Cash and share count

  • Cash balance at quarter end: Cash and cash equivalents were $3.8 million at June 30, 2026, against $6.5 million at March 31, 2026 and $1.5 million at December 31, 2025. Source
  • Non-GAAP share count rose: Non-GAAP shares outstanding, basic and diluted, were 6,269 thousand for the quarter, against 1,581 thousand in the first quarter, per the prior release. Source
  • Form 10-Q filed the day before: The unaudited results for the three and six months ended June 30, 2026 were filed on Form 10-Q on August 13, 2026, the day before this release. Source

Coming up, as management said on 14 August 2026

  • Octeris clinical validation study planned: After completing the FDA pre-submission draft, Octeris is preparing a clinical validation study at the University of North Carolina. No date was given. Source
  • Monitor moves to final clinical testing: Veris's implantable monitor is to move to final clinical testing after preliminary verification and validation. Source

Figures management reported

FigureReported
EsoGuard tests processed Source2,770 in 2Q26
EsoGuard Esophageal DNA Test revenue recognized Source$1.5 million in 2Q26

Earlier plans management reported on

  • On track: Management states the relaunched device portfolio is on track, with PortIO and Octeris progressing toward key milestones. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.